Breaking Finance News

A statement released earlier today by H.C. Wainwright about Radius Health (NASDAQ:RDUS) bumps the target price to $71.00

H.C. Wainwright bumped up the target of Radius Health (NASDAQ:RDUS) to $71.00 stating a potential upside of 0.25%.

On 8/4/2016, Maxim Group released a statement for Radius Health (NASDAQ:RDUS) bumped up the target price from $0.00 to $24.00 that suggested a downside of -0.53%.

Boasting a price of $56.73, Radius Health (NASDAQ:RDUS) traded -1.55% lower on the day. With the last stock price close up 36.68% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Radius Health has recorded a 50-day average of $55.24 and a two hundred day average of $41.35. Volume of trade was down over the average, with 401,316 shares of RDUS changing hands under the typical 942,883

Performance Chart

Radius Health (NASDAQ:RDUS)

With a total market value of $0, Radius Health has with a one year low of $24.75 and a one year high of $77.10 .

A total of 6 equity analysts have released a ratings update on RDUS. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $59.83.

Brief Synopsis About Radius Health (NASDAQ:RDUS)

Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *